ITIH2 and breast cancer: In spite of a remarkably strong downregulation of the ITIH molecules in a variety of human solid tumors, we were not able to demonstrate a statistically significant association between loss of ITIH2 expression in breast cancer and reduced overall survival (p = 0.386) or shorter recurrence-free survival (p = 0.948) in Kaplan-Meier analysis.